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Glycobiology is not a glamorous 
discipline. As a founding technology 
for Oxford GlycoSciences pic (OGS; 
Oxford, UK) it was solid but dull. 
Companies like Genentech Inc. 
(South San Francisco, California) 
needed the sugars on their protein 
drugs analyzed, and OGS were the 
people to do it. The sugar theme 
continued in the study of a few 
obscure genetic diseases involving 
defective sugar metabolism. But then 
there came two fateful events: OGS 
bought a division of Millipore 
Corporation (Bedford, Massachusetts) 
that sold two-dimensional (2D)-gel 
systems; and the Board of Directors 
of Genentech asked their CEO, G. 
Kirk Raab, to resign. 
Although OGS was doing some 
work for Genentech, Raab had never 
heard of them. But a friend told Raab 
that OGS was looking for precisely 
the person that Raab was hoping to 
become: a benevolent and powerful 
business adviser who could remake 
companies and bring in plenty of 
cash. Raab became the non­
executive Chairman of OGS. In short 
measure he replaced the majority of 
management, hired a new CEO, and 
raised ()ver £13 million in venture 
capital. Less than four years later, 
OGS is poised to move into new 
quarters in Oxfordshire, UK. The 
new facility will allow OGS to run 
100,000 20 gels per year, and 
identify the proteins on those gels at 
a rate of 1000 per day. Glycobiology 
and modesty are dead; long live 
proteomics and grand ambition. 
This new science amazes me 
"In 1996 people hardly knew what 
proteomics meant," says Raab. The 
same could be said for many people 
today. In proteomics, much has been 
claimed, but far less has been 
demonstrated. 
Proteomics has the same 
theoretical basis as its more developed 
cousin, transcription profiling. Ifyou 
can detect and quantify thousands of 
mRNAs (or proteins), then you can 
compare the profiles of any two states: 
diseased versus non-diseased, drug­
treated versus non-drug-treated. If the 
amount of an mRNA (or protein) goes 
up or down, you have a potential 
disease marker, drug target, or 
mediator of drug action or toxicity. 
Not content with finding every 
gene, OGS wants every protein. 
Post-transcriptional controls can 
make mRNA levels misleading. And, 
thanks to post-translational 
modifications, "the human proteome 
may be five to ten times bigger than 
the genome," says Andrew Lyall, 
formerly the Head of Bioinformatics 
at Glaxo Wellcome and now chief 
information officer at OGS. Once 
drug researchers start experimenting, 
that vast resource just keeps 
expanding. "Every time you give a 
new drug," says Lyall, "you've got a 
new proteome." 
Fishing expeditions 
So what to do with all this 
information? Just as with transcription 
profiling, proteomics can be used to 
find disease targets, based on their 
increased expression levels in a 
disease state. But proteomics runs 
into similar problems: there are lots of 
changes in a disease, and only a few 
of the changes are relevant to disease 
causation or possible treatment. 
Besides, there is more money and 
time spent later in the drug discovery 
process. "There's a wide array of 
technology available for target 
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discovery, so that market is reasonably 
well served," says Leigh Anderson, 
CEO of the proteomics company 
Large Scale Biology Corporation 
(Rockville, Maryland). "But there 
isn't much technology to accelerate 
development. " 
Most of the clinical samples from 
drug trials are fluids, such as serum, 
cerebrospinal fluid and urine, that do 
not contain DNA. But they do 
contain proteins, so the samples can 
be searched for surrogates of disease 
or toxicology. Disease markers can 
give early clues to a drug's efficacy, 
and toxicology profiles can quickly 
explain how a new drug is causing 
trouble. According to William Rich, 
CEO of the proteomics company 
Ciphergen Biosystems Inc. (Palo 
Alto, California), pathologists using 
proteomics have "never discovered 
so many markers in their life." 
Concepts such as these are the 
focus of an OGS deal with the 
clinical-testing company Quintiles 
Transnational Corporation (Research 
Triangle Park, North Carolina), while 
the whole spectrum of clinical and 
diagnostic markers and possible drug 
targets are under investigation in an 
Alzheimer's disease program with 
Pfizer Inc. The same logic applies to 
plants: with Pioneer Hi-Bred 
International Inc. (Des Moines, 
Iowa), OGS is looking for the basis of 
desirable seed traits. Finally, OGS is 
getting into the business of selling 
information in a deal with Incyte 
Pharmaceuticals Inc. (Palo Alto, 
California), who are providing 
software and informatics to go with 
the data generated by OGS. 
How to see all those proteins 
The core of proteomics is the ability 
to detect tiny amounts of protein 
using mass spectrometry (MS). 
Methods for generating and 
detecting ions of biological molecules 
have evolved rapidly in the last 20 
years, with sub-picomole detection 
now common, and low femtomole 
detection becoming routine. 
Before detection comes separation. 
The standard technology here is 20 
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gels. Sorting by charge in one 
dimension then size in the second 
dimensiop. gives an array of spots 
numbering in the thousands, although 
many of those spots represent the 
same protein with different 
modifications. Proteomics companies 
lay claim to various improvements on 
the basic method, including larger 
gels, new matrices, and gels bonded to 
glass for storage, but, as Anderson 
says, "you have to wonder about a 
technique that was invented 24 or 25 
years ago and is still in use." 
And there is plenty to wonder 
about. Estimates of the number of 
genes expressed in a given cell type 
range from 10,000 to 30,000, so the 
few thousand spots on a standard 20 
gel fall well short of identifying all 
proteins. Proteins that are small, low 
in abundance, or membrane-bound 
are systematically excluded. And the 
technology is expensive, 
cumbersome, and notoriously open to 
operator error. "It's very 
multifactorial," says Anderson. But, he 
says, making the process reproducible 
is "what the commercial sector can do. 
One person's hocus pocus is the other 
person's proprietary technology." 
OGS is using other protein analysis 
methods such as immunoprecipitation 
of protein complexes, and labeling of 
membrane proteins followed by 
ligand-based purification. "Proteomics 
to us means a lot more than 20 gels," 
says Raj Parekh, the chief scientific 
officer at OGS. "The key is the mass 
spectrometry and the informatics." 
But OGS has made a huge investment 
in 20 gels, and for now they rely 
heavily on this imperfect technology. 
"The most important question," says 
Anderson, "is, what is the alternative? 
I don't see any." 
The trouble with chips 
Transcription profilers have put all 
their genes on chips, so perhaps a 
protein chip can rescue researchers 
stuck in a maze of 20-gel dots. 
Ciphergen have made a modest start 
in this direction by creating chips 
with various surface chemistries. 
With combinatorial variations of chip 
surfaces and washing conditions, 
researchers can trap a few hundred 
proteins on a given chip. Mass 
spectrometry from the chip surface is 
then used to look for expression 
differences between two biological 
samples. The system is simple to 
use, can handle crude and minute 
samples, and can be tuned to focus 
on the proteins that 20 gels miss. 
"We're designing this to complement 
and not compete with technologies 
like 20 gels," says Ciphergen senior 
scientist Enrique Oalmasso. 
Replacing 20 gels will take a more 
ambitious program. One possibility is 
an antibody array, where the binding 
of uniformly labeled proteins is 
detected by fluorescence. Generating 
the antibodies for such a chip "is a 
potentially tremendous hurdle 
because what you need is exquisitely 
specific antibodies," says Parekh. 
Alternatives such as aptamers or 
various chemical surfaces may turn out 
to be more reasonable, but any chip 
system will have to deal with the huge 
dynamic range of protein expression, 
and the difficulty of keeping a diverse 
group of proteins soluble, folded, and 
competent for binding. 
"It's not the fault of the 
technology, it's the fault of proteins," 
says Anderson. "Nucleic acids are 
basically all the same but proteins are 
very heterogeneous, so it's always 
going to be more difficult to get 
proteins to behave." 
Parekh says protein chips are 
"worth pursuing, but we're quite a 
way from them having discovery 
potential." Even a successful protein 
chip is unlikely to do away with the 
trusty 20 gels. "I don't see that there 
will be one all-encompassing 
technology that becomes the only 
way to do proteomics," says Parekh. 
"Because of the greater 
physicochemical diversity of proteins 
that is an unreasonable goal." 
The difficulty of dealing with 
proteins on chips gives Raab some 
comfort. "That makes me confident," 
he says, "that what we are doing 
[with 20 gels] will remain useful for a 
very long period of time." 
Who needs a gel? 
Rpedi Aebersold at the University of 
Washington in Seattle is looking for 
another alternative to 20 gels. 
"We're going on the assumption that 
the technology that will ultimately be 
used for analysis of the proteome has 
not yet been developed," he says. 
The key for Aebersold, a member 
of the OGS scientific advisory board, 
is quantitation. The problem is that 
. .
successive runs In a mass 
spectrometer cannot be used for 
accurate comparisons. Aebersold's 
solution is to label two samples with 
a single reagent. One sample gets the 
isotopically heavy reagent, and the 
other the isotopically light reagent. 
The mixture is then put in a single 
liquid chromatography system 
followed by tandem mass 
spectrometry. Proteins from the two 
samples emerge as matched pairs, 
and can be quantified and identified 
in one fell swoop. 
Growing fast 
Technology such as Aebersold's will 
be vital for OGS, but Parekh says 
that aggressive financing is, if 
anything, more important. "Our 
approach has been to get big first," 
he says. "We've invested a lot 
internally in the hope that we will 
recoup it later." 
"Cash is so important," he 
continues. "The successful 
technology companies that have 
grown required enormous investments 
in cash to get them going. The pack 
snapping at their heels behind them 
are still snapping at their heels 
because they have been cash starved." 
For some at the company it is 
already time to declare victory. 
"People thought they'd get more 
mileage out of transcription profiling 
because it would take so much 
longer to get proteomics going," says 
Lyall. "OGS has sorted out 
proteomics so quickly that we've 
really caught people by surprise." 
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